Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
PLoS One ; 16(5): e0246053, 2021.
Artículo en Inglés | MEDLINE | ID: covidwho-1247640

RESUMEN

BACKGROUND: Cardiovascular disease (CVD) is a leading cause of health loss and health sector economic burdens in high-income countries. Unemployment is associated with increased risk of CVD, and so there is concern that the economic downturn associated with the COVID-19 pandemic will increase the CVD burden. AIMS: This modeling study aimed to quantify potential health loss, health cost burden and health inequities among people with CVD due to additional unemployment caused by COVID-19 pandemic-related economic disruption in one high-income country: New Zealand (NZ). METHODS: We adapted an established and validated multi-state life-table model for CVD in the national NZ population. We modeled indirect effects (ie, higher CVD incidence due to high unemployment rates) for various scenarios of pandemic-related unemployment projections from the NZ Treasury. RESULTS: We estimated the potential CVD-related heath loss in NZ to range from 23,300 to 36,900 health-adjusted life years (HALYs) for the different unemployment scenarios. Health inequities would be increased with the per capita health loss for Maori (Indigenous population) estimated to be 3.7 times greater than for non-Maori (49.9 vs 13.5 HALYs lost per 1000 people). The estimated additional health system costs ranged between (NZ$303 million [m] to 503m in 2019 values; or US$209m to 346m). CONCLUSIONS AND POLICY IMPLICATIONS: Unemployment due to the COVID-19 pandemic could cause significant health loss, increase health inequities from CVD, and impose additional health system costs in this high-income country. Prevention measures should be considered by governments to reduce this risk, including additional job creation programs and measures directed towards the primary prevention of CVD.


Asunto(s)
COVID-19 , Enfermedades Cardiovasculares , Modelos Económicos , Pandemias/economía , SARS-CoV-2 , Desempleo , COVID-19/complicaciones , COVID-19/economía , COVID-19/epidemiología , Enfermedades Cardiovasculares/economía , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/etiología , Análisis Costo-Beneficio , Costos de la Atención en Salud , Humanos , Nueva Zelanda/epidemiología
2.
Glob Heart ; 16(1): 18, 2021 03 15.
Artículo en Inglés | MEDLINE | ID: covidwho-1175699

RESUMEN

The current pandemic of SARS-COV 2 infection (Covid-19) is challenging health systems and communities worldwide. At the individual level, the main biological system involved in Covid-19 is the respiratory system. Respiratory complications range from mild flu-like illness symptoms to a fatal respiratory distress syndrome or a severe and fulminant pneumonia. Critically, the presence of a pre-existing cardiovascular disease or its risk factors, such as hypertension or type II diabetes mellitus, increases the chance of having severe complications (including death) if infected by the virus. In addition, the infection can worsen an existing cardiovascular disease or precipitate new ones. This paper presents a contemporary review of cardiovascular complications of Covid-19. It also specifically examines the impact of the disease on those already vulnerable and on the poorly resourced health systems of Africa as well as the potential broader consequences on the socio-economic health of this region.


Asunto(s)
COVID-19/fisiopatología , Enfermedades Cardiovasculares/fisiopatología , Síndrome Coronario Agudo/economía , Síndrome Coronario Agudo/etiología , Síndrome Coronario Agudo/fisiopatología , África , Antimaláricos/efectos adversos , Arritmias Cardíacas/economía , Arritmias Cardíacas/etiología , Arritmias Cardíacas/fisiopatología , COVID-19/complicaciones , COVID-19/economía , Enfermedades Cardiovasculares/economía , Enfermedades Cardiovasculares/etiología , Cloroquina/efectos adversos , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/fisiopatología , Atención a la Salud/economía , Factores Económicos , Recesión Económica , Producto Interno Bruto , Recursos en Salud/economía , Recursos en Salud/provisión & distribución , Insuficiencia Cardíaca/economía , Insuficiencia Cardíaca/etiología , Insuficiencia Cardíaca/fisiopatología , Humanos , Hidroxicloroquina/efectos adversos , Inflamación , Isquemia Miocárdica/economía , Isquemia Miocárdica/etiología , Isquemia Miocárdica/fisiopatología , Miocarditis/economía , Miocarditis/etiología , Miocarditis/fisiopatología , SARS-CoV-2 , Síndrome Respiratorio Agudo Grave/complicaciones , Síndrome Respiratorio Agudo Grave/fisiopatología , Factores Socioeconómicos , Cardiomiopatía de Takotsubo/economía , Cardiomiopatía de Takotsubo/etiología , Cardiomiopatía de Takotsubo/fisiopatología
3.
J Investig Med ; 69(7): 1372-1376, 2021 10.
Artículo en Inglés | MEDLINE | ID: covidwho-1133307

RESUMEN

We performed a retrospective study of cardiology telemedicine visits at a large academic pediatric center between 2016 and 2019 (pre COVID-19). Telemedicine patient visits were matched to data from their previous in-person visits, to evaluate any significant differences in total charge, insurance compensation, patient payment, percent reimbursement and zero reimbursement. Miles were measured between patient's home and the address of previous visit. We found statistically significant differences in mean charges of telemedicine versus in-person visits (2019US$) (172.95 vs 218.27, p=0.0046), patient payment for telemedicine visits versus in-person visits (2019US$) (11.13 vs 62.83, p≤0.001), insurance reimbursement (2019US$) (65.18 vs 110.85, p≤0.001) and insurance reimbursement rate (43% vs 61%, p=0.0029). Rate of zero reimbursement was not different. Mean distance from cardiology clinic was 35 miles. No adverse outcomes were detected. This small retrospective study showed cost reduction and a decrease in travel time for families participating in telemedicine visits. Future work is needed to enhance compensation for telemedicine visits.


Asunto(s)
Atención Ambulatoria , Servicio de Cardiología en Hospital , Enfermedades Cardiovasculares , Costos y Análisis de Costo , Telemedicina , Atención Ambulatoria/economía , Atención Ambulatoria/métodos , Atención Ambulatoria/organización & administración , COVID-19/epidemiología , Servicio de Cardiología en Hospital/economía , Servicio de Cardiología en Hospital/tendencias , Enfermedades Cardiovasculares/economía , Enfermedades Cardiovasculares/epidemiología , Enfermedades Cardiovasculares/terapia , Niño , Ahorro de Costo/métodos , Costos y Análisis de Costo/métodos , Costos y Análisis de Costo/estadística & datos numéricos , Salud de la Familia , Femenino , Accesibilidad a los Servicios de Salud/economía , Cardiopatías Congénitas/economía , Cardiopatías Congénitas/epidemiología , Cardiopatías Congénitas/terapia , Humanos , Masculino , Estudios Retrospectivos , SARS-CoV-2 , Telemedicina/economía , Telemedicina/organización & administración , Telemedicina/estadística & datos numéricos , Estados Unidos/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA